Lupin Q2 FY27 results reveal a 22% net profit decline despite revenue growth, highlighting rising expenses and margin pressures.
Hikma's branded drug growth is strengthening its 2026 outlook, with cardiovascular, diabetes and CNS medicines gaining momentum despite continued weakness in injectables revenue.
Evommune's USD 1.1 billion Hinova deal advances a VAV1 degrader targeting autoimmune diseases, putting protein degradation technology and rheumatoid arthritis development in focus.
Alembic Pharma’s Q2 surge highlights a changing growth engine, with US formulations, domestic branded medicines and API operations driving earnings.
AstraZeneca’s 10 billion bid for Rhythm Pharmaceuticals highlights how obesity science is becoming a strategic priority beyond mainstream weight-loss treatments.
AbbVie expands Oxford research capabilities, strengthening drug discovery through biotechnology expertise, academic partnerships and new disease target exploration.
Asia Healthcare Holdings (AHH) is driving Asian Institute of Nephrology and Urology (AINU)'s next phase of growth and expansion with the launch of its super-specialized uro-nephrology hospital in Bhubaneswar, marking its entry into Odisha.
Sterile drug manufacturing faces tighter contamination controls as India proposes WHO-aligned microbial limits, placing cleanroom monitoring and pharmaceutical quality assurance under greater scrutiny.
Sino Biopharmaceutical’s USD 7 billion oncology agreement highlights preclinical oncology licensing and the company's expanding strategy of partnering its drug pipeline with global pharmaceutical groups.
Nurix loses a potential USD 455 million milestone opportunity after Sanofi discontinues its STAT6 degrader programme, raising questions about targeted protein degradation in autoimmune drug development.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
